title: Quality of life with rivaroxaban in patients with non-valvular atrial fibrilation by therapeutic compliance.
abstract: To assess the quality of life (QOL) with rivaroxaban in patients with non-valvular atrial fibrilation (NVAF) related to therapeutic compliance.
  
  
  
  Prospective, longitudinal, multicenter study was developed in 160 Spanish primary or specialized care centers. We included 412 patients treated with rivaroxaban, prescribed for stroke prevention. Three visits were conducted: baseline, 6 and 12 months. Compliance was measured by electronic monitoring systems. QOL was measured by a specific questionnaire. We calculated the percentage of compliance means, the percentage of daily compliers and the score of QOL.
  
  
  
  Three hundred and seventy patients finished the study (mean age 75.19 SD: 7.5 years). Daily compliance was 83.5% (CI 78.53-88.57%) (n = 309) and 80% (CI 74.65-85.35%) at 6 and 12 months, respectively. Average QOL rating was 112.85 (SD 29.31) in non-compliant and 111.80 (SD 29.31) in the compliant group (p = Not significant), and after 12 months of 124.67 (SD 30.78) and 83.47 (SD 26.44), respectively (p < 0.0001), with a decrease in the score compliers (p < 0.01) and an increase in non-compliant group (p < 0.05). A higher number of drugs consumed, as well as the number of diseases/conditions suffered, the older age of the patients and having been previously treated with VKA were associated with a higher overall score (worse QOL).
  
  
  
  QOL in NVAF patients treated with rivaroxaban improved significantly over the study group at the expense of compliers. A worse QOL was associated with pluripathology, polymedication, older patients and previous treatment with VKA.
authors.affiliation: Unidad de Gestión Clínica La Orden, C/PUERTO, 6º D, 21003, Huelva, Spain. emarquezc@medinautic.com.
authors.forename: Emilio
authors.initials: E
authors.lastname: Márquez-Contreras
authors.affiliation: Medicina Interna, Hospital San Carlos Madrid, Madrid, Spain.
authors.forename: Nieves
authors.initials: N
authors.lastname: Martell-Claros
authors.affiliation: Universidad de Medicina, Elche, Alicante, Spain.
authors.forename: Vicente
authors.initials: V
authors.lastname: Gil-Guillén
authors.affiliation: ABS Sardenya, Barcelona, Spain.
authors.forename: Mariano
authors.initials: M
authors.lastname: De la Figuera-Von Wichmann
authors.affiliation: Centro Salud Puerto Santa María, Cadiz, Spain.
authors.forename: Eugenio
authors.initials: E
authors.lastname: Sánchez-López
authors.affiliation: ABS Vieilla, Lleida, Spain.
authors.forename: Ines
authors.initials: I
authors.lastname: Gil-Gil
authors.affiliation: Unidad de Gestión Clínica La Orden, C/PUERTO, 6º D, 21003, Huelva, Spain.
authors.forename: Sara
authors.initials: S
authors.lastname: Márquez-Rivero
mesh_terms: D000368:Aged; D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000188:drug therapy / Q000523:psychology*; D005260:Female; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D010349:Patient Compliance; D011446:Prospective Studies; D011788:Quality of Life; D000069552:Rivaroxaban / Q000008:administration & dosage / Q000627:therapeutic use; D013030:Spain
chemical_list: D000925:Anticoagulants; D000069552:Rivaroxaban
keywords: Health-related quality of life; Non-valvular atrial fibrillation; Orals anticoagulants; Preventing stroke; Rivaroxaban; Therapeutic compliance